ADC Therapeutics (ADCT) Research & Development (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Research & Development of $19.9 million for Q1 2026, down 31.29% year-on-year from $28.9 million in Q1 2025, and down 25.84% on a QoQ basis from $26.8 million in Q3 2025.
ADC Therapeutics (ADCT) Research & Development (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Research & Development for 7 consecutive years, with $19.9 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | 19.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.88 Mn |
| Sep 30, 2025 | 26.80 Mn |
| Jun 30, 2025 | 30.09 Mn |
| Mar 31, 2025 | 28.93 Mn |
| Sep 30, 2024 | 32.50 Mn |
| Jun 30, 2024 | 24.30 Mn |
| Mar 31, 2024 | 25.74 Mn |
| Sep 30, 2023 | 27.08 Mn |
| Jun 30, 2023 | 31.34 Mn |
| Mar 31, 2023 | 39.48 Mn |
| Sep 30, 2022 | 41.68 Mn |
| Jun 30, 2022 | 48.54 Mn |
| Mar 31, 2022 | 48.95 Mn |
| Sep 30, 2021 | 36.81 Mn |
| Jun 30, 2021 | 39.53 Mn |
| Mar 31, 2021 | 39.17 Mn |
| Sep 30, 2020 | 32.16 Mn |
| Jun 30, 2020 | 25.95 Mn |
| Mar 31, 2020 | 35.38 Mn |